Hypertension and COVID-19: Updates from the era of vaccines and variants

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for coronavirus disease 2019 (COVID-19) has been a major cause of morbidity and mortality globally. Older age, and the presence of certain components of metabolic syndrome, including hypertension have been associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Swamy, Sowmya, Koch, Christian A., Hannah-Shmouni, Fady, Schiffrin, Ernesto L., Klubo-Gwiezdzinska, Joanna, Gubbi, Sriram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Special Issue: COVID19 and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645507/
https://www.ncbi.nlm.nih.gov/pubmed/34900602
http://dx.doi.org/10.1016/j.jcte.2021.100285
Descripción
Sumario:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for coronavirus disease 2019 (COVID-19) has been a major cause of morbidity and mortality globally. Older age, and the presence of certain components of metabolic syndrome, including hypertension have been associated with increased risk for severe disease and death in COVID-19 patients. The role of antihypertensive agents in the pathogenesis of COVID-19 has been extensively studied since the onset of the pandemic. This review discusses the potential pathophysiologic interactions between hypertension and COVID-19 and provides an up-to-date information on the implications of newly emerging SARS-CoV-2 variants, and vaccines on patients with hypertension.

Ejemplares similares